The epidermal growth factor receptor: A link between inflammation and liver cancer

Experimental Biology and Medicine

Volumn 234, Issue 7, 2009, Pages 713-725

  Berasain, Carmen ^a   Perugorria, Maria J ^a   Latasa, Maria Ujue ^a   Castillo, Josefa ^a   Goñi, Saioa ^a   Santamaría, Mónica ^a   Prieto, Jesús ^a,b   Avila, Matías A ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Amphiregulin; Epidermal growth factor receptor; Heparin binding epidermal growth factor like growth factor; Hepatocellular carcinoma; Inflammation; Liver

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GEMCITABINE; LAPATINIB; OXALIPLATIN; TRANSFORMING GROWTH FACTOR BETA;

CLINICAL TRIAL; DISSECTION; HEPATITIS; HUMAN; KIDNEY FIBROSIS; LIVER CELL CARCINOMA; LIVER INJURY; LUNG NON SMALL CELL CANCER; NONHUMAN; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REAL TIME POLYMERASE CHAIN REACTION; SHORT SURVEY;

ANIMALS; CARCINOMA, HEPATOCELLULAR; DISEASE MODELS, ANIMAL; HEPATITIS; HUMANS; LIVER NEOPLASMS; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 67650227488     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.3181/0901-MR-12     Document Type: Short Survey

References (123)

1. El-Serag HB, Rudolph L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557-2576, 2007.
2. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis 25:143-154, 2005.
3. Marrero CR, Marrero JA. Viral hepatitis and hepatocellular carcinoma. Arch Med Res 38:612-620, 2007.
4. Kremsdorf D, Soussan P, Paterlini-Brechot P, Brechot C. Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. Oncogene 25:3823-3833, 2006.
5. Lupberger J, Hildt E. Hepatitis B virus-induced oncogenesis. World J Gastroenterol 13:74-81, 2007.
6. Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 25:3834-3847, 2006.
7. Seitz HK, Stickel F. Molecular mechanisms of alcohol-mediated carcinogenesis. Nat Rev Cancer 7:599-612, 2007.
8. Laurent-Puig P, Zucmann-Rossi J. Genetics of hepatocellular tumors. Oncogene 25:3778-3786, 2006.
9. Breuhahn K, Longerich T, Schirmacher P. Dysregulation of growth factor signalling in human hepatocellular carcinoma. Oncogene 25:3787-3800, 2006.
10. Fausto N, Campbell JS, Riehle KJ. Liver regeneration. Hepatology 43:S45-S53, 2006.
11. Michalopoulos GK. Liver regeneration. J Cell Physiol 213:286-300, 2007.
12. Muddu AK, Guha IN, Elsharkawy AM, Mann DA. Resolving fibrosis in the diseased liver: translating the scientific promise to the clinic. Int J Biochem Cell Biol 39:695-714, 2007.
13. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6:674-687, 2006.
14. Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. Oncogene 25:3866-3884, 2006.
15. Avila MA, Berasain C, Torres L, Martín-Duce A, Corrales FJ, Yang H, Prieto J, Lu SC, Caballería J, Rodés J, Mato JM. Reduced mRNA abundante of the main enzymes envolved in methionine metabolismo in human liver cirrosis and hepatocellular carcinoma. J Hepatol 33:907-914, 2000.
16. Berasain C, Herrero JI, García-Trevijano ER, Avila MA, Esteban JI, Mato JM, Prieto J. Expression of Wilms' tumor supresor in the liver with cirrosis: relation to hepatocyte nuclear factor 4 and hepatocellular function. Hepatology 38:148-157, 2003.
17. Perugorria MJ, Castillo J, Latasa MU, Goñi S, Segura V, Sangro B, Prieto J, Avila MA, Berasain C. Wilms' tumor 1 gene (WT1) expression in hepatocellular carcinoma promotes cell dedifferentiation and resistance to chemotherapy. Cancer Res In press, 2009.
18. Budhu A, Wang XW. The role of cytokines in hepatocellular carcinoma. J Leukocyte Biol 80:1197-1213, 2006.
19. Elsharkawy A M, Mann DA. Nuclear factor-κB and the hepatic inflammation-fibrosis-cancer axis. Hepatology 46:590-597, 2007
20. Naugler WE, Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 14:109-117.
21. Lee JS, Thorgeirsson SS. Comparative and integrative functional genomics of HCC. Oncogene 25:3801-3809, 2006.
22. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 134:1655-1669, 2008
23. Markiewski MM, DeAngelis RA, Lambris JD. Liver inflammation and regeneration: two distinct biological phenomena or parallel pathophysiologic processes? Mol Immunol 43:45-56, 2006.
24. Sakurai T, He G, Matsuzawa A, Yu GY, Maeda S, Hardiman G, Karin M. Hepatocyte necrosis induced by oxidative stress and IL-1α release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell 14:156-165, 2008.
25. Henderson NC, Iredale JP. Liver fibrosis: cellular mechanisms of progression and resolution. Clin Sci 112:265-280, 2007.
26. Seki E, Brenner DA. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 48:322-335, 2008.
27. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: mechanisms linking microbial infections to chronic inflammatory disorders and cancer. Cell 124:823-835, 2006.
28. Mollen KP, Anand RJ, Tsung A, Prince JM, Levy RM, Billiar TR. Emerging paradigm: Toll-like receptor 4-sentinel for the detection of tissue damage. Shock 26:430-437, 2006.
29. Chen CJ, Kono H, Golenbock D, Reed G, Akira S, Rock KL. Identification of a key pathway required for sterile inflammatory response by dying cells. Nat Med 13:851-856, 2007.
30. Zhang Z, Schluesener HJ. Mammalian toll-like receptors: from endogenous ligands to tissue regeneration. Cell Mol Life Sci 63:2901-2907, 2006.
31. Su GL, Wang SC, Aminlari A, Tipoe GL, Steinstraesser L, Nanji A. Impaired hepatocyte regeneration in toll-like receptor 4 mutant mice. Dig Dis Sci 49:843-849, 2004.
32. Sakurai T, He G, Matsuzawa A, Yu GY, Maeda S, Hardiman G, Karin M. Hepatocyte necrosis induced by oxidative stress and IL-1α release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell 14:156-165, 2008.
33. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317:121-124, 2007.
34. Naugler WE, Karin M. NF-κB and cancer-identifying targets and mechanisms. Curr Opin Genet & Devel 18:19-26, 2008.
35. Schäfer B, Gschwind A, Ullrich A. Multiple G-protein-coupled receptor signals converge on the epidermal growth factor receptor to promote migration and invasion. Oncogene 23:991-999, 2004.
36. Berasain C, Castillo J, Prieto J, Avila MA. New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system. Liver Int 27:174-185, 2007.
37. Fabregat I, Roncero C, Fernández M. Survival and apoptosis: a dysregulated balance in liver cancer. Liver Int 27:155-162, 2007.
38. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 23:254-266, 2005.
39. Rozengurt E. Mitogenic signalling pathways induced by G protein-coupled receptors. J Cell Physiol 213:589-602, 2007.
40. Wu T. Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treat Reviews 32:28-44, 2006.
41. Fukata M, Abreu MT. Role of Toll-like receptors in gastrointestinal malignancies. Oncogene 27:234-243, 2008.
42. Shepard HM, Brdlik CM, Schreiber H. Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. J Clin Invest 118:3574-3581, 2008.
43. Sibilia M, Kroismayr R, Lichtenberger BM, Natarajan A, Hecking M, Holcmann M. Differentiation 75:770-787, 2007.
44. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7:505-516, 2006.
45. Harris RC, Chung E, Coffey RJ. EGF receptor ligands. Exp Cell Res 284:2-13, 2003.
46. Berasain C, Castillo J, Perugorría MJ, Prieto J, Avila MA. Cancer Lett 254:30-41, 2007.
47. Higashiyama S, Iwabuki H, Morimoto C, Hieda M, Inoue H, Matsushita N. Membrane-anchored growth factors, the epidermal growth factor family; beyond receptor ligands. Cancer Sci 99:214-220, 2008.
48. Schneider MR, Wolf E. The epidermal growth factor receptor ligands at a glance. J Cell Physiol Nov 12. [Epub ahead of print], 2008.
49. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 284:31-53, 2003.
50. Ohtsu H, Dempsey PJ, Eguchi S. ADAMs as mediators of EFR receptor transactivation by G protein-coupled receptors. Am J Physiol Cell Physiol 291:C1-C10, 2006.
51. Kenny PA. Tacling EGFR signalling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer. Expert Opin Ther Targets 11:1287-1298, 2007.
52. Sahin U, Weskamp G, Kelly K, Zhou HM, Higashiyama S, Peschon J, Hartmann D, Saftig P, Blobel CP. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 164:769-779, 2004.
53. Sternlicht MD, Sunnarborg SW. J Mammary Gland Biol Neoplasia 13:181-194, 2008.
54. Higashiyama S, Nanba D. ADAM-mediated ectodomain shedding of HB-EGF in receptor crosstalk. Biochim Biophys Acta 1751:110-117, 2005.
55. Fischer OM, Hart S, Gschwind A, Ullrich A. EGFR signal transactivation in cancer cells. Biochem Soc Trans 31:1203-1208, 2003.
56. Al-Salihi, Ulmer SC, Doan T, Nelson CD, Crotty T, Prescott SM, Stafforini DM, Topham MK. Cyclooxygenase-2 transactivates the epidermal growth factor receptor through specific E-prostanoid receptors and tumor necrosis factor-a converting enzyme. Cell Signal 19:1956-1963, 2007.
57. Subbaramaiah K, Benezra R, Hudis C, Dannenberg AJ. Cyclooxygenase-2 derived prostaglandin E2 stimulates Id-1 transcription. J Biol Chem 283:33955-33968, 2008.
58. Pastore S, Mascia F, Mariani V, Girolomoni G. The epidermal growth factor receptor system in skin repair and inflammation. J Invest Dermatol 128:1365-1374, 2008.
59. Farley SM, Purdy DE, Ryabinia OP, Schneider P, Magun BE, Iordanov MS. Fas ligand-induced proinflammatory transcriptional responses in reconstructed human epidermis. J Biol Chem 283:919-928, 2008.
60. Burgel PR, Nadel JA. Epidermal growth factor receptor-mediated innate immune responses and their roles in airway diseases. Eur Respir J 32:1068-1081, 2008.
61. Koff JL, Shao MXG, Ueki IF, Nadel JA. Multiple TLRs activate EGFR via a signaling cascade to produce innate immune responses in airway epithelium. Am J Physiol Lung Cell Mol Physiol 294:L1068-L1075, 2008.
62. Liu K, Gualano RC, Hibbs ML, Anderson GP, Bozinovski S. Epidermal growth factor receptor signaling to Erk1/2 and STATs control the intensity of the epithelial inflammatory responses to rhinovirus infection. J Biol Chem 283:9977-9985, 2008.
63. Liu K, Anderson GP, Bozinovski S. DNA vector augments inflammation in epithelial cells via EGFR-dependent regulation of TLR4 and TLR2. Am J Respir Cell Mol Biol 39:305-311, 2008.
64. Liu M, Yang S, Sharma S, Luo J, Cui X, Peebles KA, Huang M, Sato M, Ramirez RD, Shay JW, Minna JD, Dubinett SM. EGFR signaling is required for TGF-b1-mediated Cox-2 induction in human bronchial epithelial cells. Am J Respir Cell Mol Biol 37:578-588, 2007.
65. Tanida S, Joh T, Itoh K, Kataoka H, Sasaki M, Ohara H, Nakazawa T, Nomura T, Kinugasa Y, Ohmoto H, Ishiguro H, Yoshino K, Higashiyama S, Itoh M. The mechanism of cleavage of EGFR ligands induced by inflammatory cytokines in gastric cancer cells. Gastroenterology 127:559-569, 2004.
66. Van Schaeybroeck S, Kelly DM, Kyula J, Stokesberry S, Fennell DA, Johnston PG, Longley DB. Src and ADAM-17-mediated shedding of transforming growth factor-α is a mechanism of acute resistance to TRAIL. Cancer Res 68:8312-8321, 2008.
67. Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, Hsu D, Xu R, Harpaz N, Dannenberg AJ, Subbaramaiah K, Cooper HS, Itzkowitz SH, Abreu MT. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 133:1869-1881, 2007.
68. Shao J, Lee SB, Guo H, Evers BM, Sheng H. Prostaglandin E2 stimulates the growth of colon cancer cells via induction of amphiregulin. Cancer Res 63:5218-5223, 2003.
69. Keates S, Han X, Kelly CP, Keates AC. Macrophage-inflammatory protein-3a mediates epidermal growth factor receptor transactivation and ERK1/2 MAPK signalling in Caco-2 colonic epithelial cells via metalloproteinase-dependent release of amphiregulin. J Immunol 178:8013-8021, 2007.
70. Merchant NB, Voskrensensky I, Rogers CM, LaFleur B, Dempsey PJ, Graves-Deal R, Revetta F, Foutch AC, Rothenberg ML, Washington MK, Coffey RJ. TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer. Clin Cancer Res 14:1182-1191, 2008.
71. Natarajan A, Wagner B, Sibilia M. The EGF receptor is required for efficient liver regeneration. Proc Natl Acad Sci USA 104:17081-17086, 2007.
72. Lin XM, Liu YB, Zhou F, Wu YL, Chen L, Fang HQ. Expression of tumor necrosis factor-alpha converting enzyme in liver regeneration after partial hepatectomy. World J Gastroenterol 14:1353-1357, 2008.
73. Russell WE, Kaufmann WK, Sitaric S, Luetteke NC, Lee DC. Liver regeneration and hepatocarcinogenesis in transforming growth factor-alpha-targeted mice. Mol Carcinogen 15:183-189, 1996.
74. Lee D, Pearsall RS, Das S, Dey SK, Godfrey VL, Threadgill DW. Epiregulin is not essential for development of intestinal tumors but is required for protection from intestinal damage. Mol Cell Biol 24:8907-8916, 2004.
75. Mitchell C, Nivison M, Jackson LF, Fox R, Lee DC, Campbell JS, Fausto N. Heparin-binding epidermal growth factor-like growth factor links hepatocyte priming with cell cycle progression during liver regeneration. J Biol Chem 280:2562-2568, 2005.
76. Berasain C, Garcia-Trevijano ER, Castillo J, Lee DC, Prieto J, Avila MA. Amphiregulin: an early trigger of liver regeneration in mice. Gastroenterology 128:424-432, 2005.
77. Berasain C, Garcia-Trevijano ER, Castillo J, Erroba E, Santamaria M, Lee DC, Prieto J, Avila MA. Novel role for amphiregulin in protection from liver injury. J Biol Chem 280:19012-19020, 2005.
78. Schiffer E, Housset C, Cacheux W, Wendum D, Desbois-Mouthon C, Rey C, Clerge F, Poupon R, Barbu V, Rosmorduc O. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 41:307-314, 2005.
79. Castillo J, Erroba E, Perugorria MJ, Santamaria M, Lee DC, prieto J, Avila MA, Berasain C. Amphiregulin contribuyes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res 66:6129-6138, 2006.
80. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 115:209-218, 2005.
81. Gressner OA, Rizk MS, Kovalenko E, Weiskirchen R, Gressner AM. Changing the pathogenic roadmap of liver fibrosis?. Where did it start; where will it go? J Gastroenterol Hepatol 23:1024-1035, 2008.
82. Pinzani M, Gesualdo L, Sabbah GM, Abboud HE. Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells. J Clin Invest 84:1786-1793, 1989.
83. Gressner AM. Cytokines and cellular crosstalk involved in the activation of fat-storing cells. J Hepatol 22 (Suppl 2):28-36, 1995.
84. Yang C, Zeisberg M, Mosterman B, Sudhakar A, Yerramalla U, Holthaus K, Xu L, Eng F, Afdhal N, Kalluri R. Liver fibrosis: insights into migration of hepatic stellate cells in response to extracellular matrix and growth factors. Gastroenterology 124:147-159, 2003.
85. Perugorria MJ, Latasa MJ, Nicou A, Cartagena-Lirola H, Castillo J, Goñi S, Vespasiani-Gentilucci U, Zagami MG, Lotersztajn S, Prieto J, Berasain C, Avila MA. The epidermal growth factor receptor ligand amphiregulin participates in the development of mouse liver fibrosis. Hepatology 48:1251-1261, 2008.
86. Gallucci RM, Simeonova PP, Toriumi W, Luster MI. TNF-alpha regulates transforming growth factor-alpha expression in regenerating murine liver and isolated hepatocytes. J Immunol 164:872-878, 2000.
87. Sagmeister S, Drucker C, Losert A, Grusch M, Daryabeigi A, Parzefall W, Rohr-Udilova N, Bichler C, Smedsrød, Kandioler D, Grünberger T, Wrba F, Schulte-Hermann R, Grasl-Kraupp B. HBEGF is a paracrine growth stimulator for early tumor prestages in inflammation-associated hepatocarcinogenesis. J Hepatol 49:955-964, 2008.
88. Reinehr R, Sommerfeld A, Haüssinger D. CD95 ligand is a proliferative and antiapoptotic signal in quiescent hepatic stellate cells. Gastroenterology 134:1494-1506, 2008.
89. Lautrette A, Li S, Alili R, Sunnarborg SW, Burtin M, Lee DC, Friedlander G, Terzi F. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat Med 11:867-874, 2005.
90. François H, Placier S, Flamant M, Tharaux PL, Chansel D, Dussaule JC, Chatziantoniou C. Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition. FASEB J 18:926-928, 2004.
91. Drucker C, Parzefall W, Teufelhofer O, Grusch M, Ellinger A, Schulte-Hermann R, Grasl-Kraupp B. Non-parenchymal liver cells support the growth advantage in the first stages of hepatocarcinogenesis. Carcinogenesis 27:152-161, 2006.
92. Lin C-Y, Lin C-J, Chen K-H, Wu J-V, Huang S-H, Wang S-M. Macrophage activation increases the invasive properties of hepatoma cells by destabilization of the adherens junction. FEBS Lett 580:3042-3050, 2006.
93. Ding X, Yang LY, Huang GW, Wang W, Lu WQ. ADAM17 mRNA expression and pathological features of hepatocellular carcinoma. World J Gastroenterol 10:2735-2739, 2004.
94. Webber EM, Wu JC, Wang L, Merlino G, Fausto N. Overexpression of transforming growth factor-alpha causes liver enlargement and increased hepatocyte proliferation in transgenic mice. Am J Pathol 145:398-408, 1994.
95. Borlak J, Meier T, Halter R, Spanel R, Spanel-Borowski K. Epidermal growth factor-induced hepatocellular carcinoma: gene expression profiles in precursor lesions, early stage and solitary tumours. Oncogene 24:1809-19819, 2005.
96. Ortiz C, Caja L, Sancho P, Bertran E, Fabregat I. Inhibition of the EGF receptor blocks autocrine growth and increases the cytotoxic effects of doxorubicin in rat hepatoma cells. Biochem Pharmacol 75:1935-1945, 2008.
97. Murillo MM, Carmona-Cuenca I, Del Castillo G, Ortiz C, Roncero C, Sánchez A, Fernández M, Fabregat I. Activation of NADPH oxidase by transforming growth factor-β in hepatocytes mediates upregulation of epidermal growth factor receptor ligands through a nuclear factor-κB- dependent mechanism. Biochem J 405:251-259, 2007.
98. Murillo MM, Del Castillo G, Sánchez A, Fernández M, Fabregat I. Involvement of EGF receptor and c-Src in the survival signals induced by TGF-β1 in hepatocytes. Oncogene 24:4580-4587, 2005.
99. Wang SE, Xiang B, Guix M, Olivares MG, Parker J, Chung CH, Pandiella A, Arteaga CL. Transforming growth factor β engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol Cell Biol 28:5605-5620, 2008.
100. Ueno Y, Sakurai H, Matsuo M, Choo MK, Koizumi K, Saiki I. Selective inhibition of TNF-alpha-induced activation of mitogen-activated protein kinases and metastatic activities by gefitinib. Br J Cancer 92:1690-1695, 2005.
101. Matsuo M, Sakurai H, Ueno Y, Ohtani O, Saiki I. Activation of MEK/ERK and PI3K/Akt pathways by fibronectin requires integrin alpha v-mediated ADAM activity in hepatocellular carcinoma: a novel functional target for gefitinib. Cancer Sci 97:155-162, 2006.
102. Itabashi H, Maesawa C, Oikawa H, Kotani K, Sakurai E, Kato K, Komatsu H, Nitta H, Kawamura H, Wakabayashi G, Masuda T. Angiotensin II and epidermal growth factor receptor cross-talk mediated by a disintegrin and metalloprotease accelerates tumor cell proliferation of hepatocellular carcinoma cell lines. Hepatol Research 38:601-613, 2008.
103. Argast GM, Campbel JS, Brooling JT, Fausto N. Epidermal growth factor receptor transactivation mediates tumor necrosis factor-induced hepatocyte replication. J Biol Chem 279:34530-34536, 2004.
104. Bataller R, Schwaabe RF, Choi YH, Yang L, Paik YH, Lindquist J, Qian T, Schoonhoven R, Hagerdorn CH, Lemasters JJ, Brenner DA. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 112:1383-1394, 2003.
105. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 358:1160-1174, 2008.
106. Sattler M, Abidoye O, Salgia R. EGFR-targeted therapeutics: focus on SCCHN and NSCLC. The ScientificWorld Journal 8:909-919, 2008
107. Shepherd FA, Rodrigues Pereira PJ, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L, National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previosuly treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005.
108. Gridelli C, Bareschino MA, Schettino C, Rossi A, Maione P, Ciardiello F. Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist 12:840-849, 2007.
109. Fukui T, Mitsudomi T. Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers. Gen Thorac Cardiovasc Surg 56:97-103, 2008.
110. Ishikawa N, Daigo Y, Takano A, Taniwaki M, Kato T, Hayama S, Murakami H, Takeshima Y, Inai K, Nishimura H, Tsuchiya E, Kohno N, Nakamura Y. Increases of amphiregulin and transforming growth factor-α in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers. Cancer Res 65:9176-84, 2005.
111. Masago K, Fujita S, Hatachi Y, Fukuhara A, Sakuma K, Ichikawa M, Kim YH, Mio T, Mishima M. Clinical significance of pretreatment serum amphiregulin and transforming growth factor-α, and an epidermal growth factor somatic mutation in patients with advanced non-squamous, non-small cell lung cancer. Cancer Sci 99:2295-2301, 2008.
112. Höpfner M, Schuppan D, Scherübl H. Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol 14:1-14, 2008.
113. Gianelli G, Sgarra C, Porcelli L, Azzariti A, Antonaci S, Paradiso A. EGFR and VEGFR as potential target for biological therapies. Cancer Lett 262:257-264, 2008.
114. O'Dwyer PJ, Levy DE, Kauh JS, Fitzgerald DB, Benson AB III. Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern Cooperative Oncology Group's Study. J Clin Oncol 24: Abstract 4143, 2006.
115. Zhu AX, Stuart K, Blaszkowsky LS, Muzikansky A, Reitberg DP, Clark JW, Enzinger PC, Bhargava P, Meyerhardt JA, Horgan K, Fuchs CS, Ryan DP. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 110:581-589, 2007.
116. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48:1312-1327, 2008.
117. Thomas MB, Chadha R, Glover K, Wang X, Morris J, Brown T, Rashid A, Dancey J, Abbruzzese JL. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 110:1059-1066, 2007.
118. Asnacios A, Fartoux L, Romano O, Tesmoingt C, Louafi S, Mansoubakht T, Artru P, Poynard T, Rosmorduc O, Hebbar M, Taieb J. Gemcitabine plus oxaliplatin (GEMOX) combined with-cetuximab in patients with progressive advanced stage hepatocellular carcinoma. Cancer 112:2733-2739, 2008.
119. Su MC, Lien HC, Jeng YM. Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma. Cancer Lett 224:117-121, 2005.
120. Desbois-Mouthon C, Cacheux W, Blivet-Van Eggelpoël M-J, Barbu V, Fartoux L, Poupon R, Housset C, Rosmorduc O. Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib. Int J Cancer 119:2557-2566, 2006.
121. Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, Battiston C, Van Laarhoven S, Fiel MI, Di Feo A, Hoshida Y, Yea S, Toffanin S, Ramos A, Martignetti JA, Mazzaferro V, Bruix J, Waxman S, Schwartz M, Meyerson M, Friedman SL, Llovet JM. Pivotal role of mTOR signalling in hepatocellular carcinoma. Gastroenterology 135:1972-1983, 2008.
122. Merchant NB, Voskresensky I, Rogers CM, LaFleur B, Dempsey PJ, Graves-Deal R, Revetta F, Foutch AC, Rothemberg ML, Washington MK, Coffey RJ. TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer. Clin Cancer Res 14:1182-1191, 2008.
123. Bublil EM, Yarden Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol 19:124-134, 2007.